Welcome to our dedicated page for Coherus SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial costs, FDA risk, and biosimilar price dynamics turn Coherus BioSciences’ disclosures into a maze. If you have ever searched for “Coherus BioSciences SEC filings explained simply” and still wound up combing through hundreds of pages, you know the challenge.
Stock Titan resolves that pain. Our AI reads every document the moment it hits EDGAR, converts jargon into plain English, and flags what matters: revenue swings from UDENYCA®, toripalimab trial updates, and partnership royalties. Whether you need the Coherus BioSciences quarterly earnings report 10-Q filing or the latest Coherus BioSciences 8-K material events explained, you’ll get real-time alerts and concise takeaways.
Here’s what you can uncover faster than opening a PDF:
- Coherus BioSciences insider trading Form 4 transactions and Coherus BioSciences Form 4 insider transactions real-time to monitor executive sentiment.
- Coherus BioSciences annual report 10-K simplified—AI pinpoints R&D spend on ILT4, CCR8, and IL-27 antibodies.
- Coherus BioSciences proxy statement executive compensation for insight into incentive alignment.
- Coherus BioSciences earnings report filing analysis that compares biosimilar margins quarter over quarter.
Still need context? Try “understanding Coherus BioSciences SEC documents with AI” inside the platform and see segment revenue, cash runway, and risk factors distilled into a paragraph. From Coherus BioSciences executive stock transactions Form 4 to pipeline-moving 8-Ks, every filing type is covered, updated in seconds, and paired with expert commentary so you can make confident decisions without drowning in detail.
Coherus Oncology, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150.0 million of mixed securities, including common stock, preferred stock, debt securities, warrants, and units, from time to time in one or more offerings. Each sale will be detailed in a prospectus supplement describing specific terms and pricing.
The filing replaces a prior registration and, under Rule 415, permits offerings via underwriters, dealers, agents, or direct sales. The company’s common stock trades on Nasdaq as CHRS; the last reported sale price was $1.36 per share on November 12, 2025. Use of proceeds will be described in the applicable prospectus supplement.
Coherus Oncology filed a Form S-8 registering 1,500,000 additional shares of common stock for its 2014 Employee Stock Purchase Plan, as approved by stockholders on June 11, 2025.
The filing adds capacity for employee share purchases under the ESPP. It includes customary exhibits, including a legal opinion from Latham & Watkins LLP, and notes Coherus is an accelerated filer and a smaller reporting company.
Coherus Oncology (CHRS) recast prior financials to reflect discontinued operations after divesting its UDENYCA franchise. The company completed the UDENYCA sale to Intas on April 11, 2025 for upfront, all‑cash consideration of $483.4 million, which included $118.4 million for product inventory. Coherus is also eligible for two additional earn‑out payments of $37.5 million each.
Exhibit 99.1 updates selected sections of the 2024 Form 10‑K to present the biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations for the fiscal years ended December 31, 2024 and 2023. The recast information is intended for incorporation by reference into a Form S‑3 expected to be filed on November 13, 2025. The filing limits changes to those necessary for the discontinued operations presentation, maintaining the nature and character of the original disclosures.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
FAQ
What is the current stock price of Coherus (CHRS)?
What is the market cap of Coherus (CHRS)?
